In addition to peripheral effects, certain hepatokines, such as FGF-21, SELENOP, Fetuin-A, ANGPTL3, MANF, Adropin, ApoJ, and SHBG, exhibit direct or indirect effects on the CNS and represent promising therapeutic targets for AD (Figure.2). This evidence concerns the gene CLU and Alzheimer disease.